

# CITATION REPORT

List of articles citing

**Rivaroxaban for stroke prevention in atrial fibrillation:  
a critical review of the ROCKET AF trial**

**DOI: 10.1586/erc.12.91**

**Expert Review of Cardiovascular Therapy, 2012, 10, 965-72.**

**Source:** <https://exaly.com/paper-pdf/52616520/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	[Stroke prevention in atrial fibrillation : old and new anticoagulants]. <i>Herz</i> , <b>2013</b> , 38, 231-8	2.6	
7	Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2014</b> , 40, 261-8	2.4	2
6	Atrial Fibrillation: Pathophysiology and Therapeutic Options. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2015</b> , 29, 1333-40	2.1	17
5	Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , <b>2015</b> , 95, 388-99	6.8	19
4	The use of rivaroxaban for the treatment of thrombotic complications in four dogs. <i>Journal of Veterinary Emergency and Critical Care</i> , <b>2016</b> , 26, 729-36	1.7	25
3	Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2017</b> , 125, 411-422	6.8	12
2	Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?. <i>Journal of Geriatric Cardiology</i> , <b>2016</b> , 13, 226-32	1.7	25
1	Problem of prescribing anticoagulant therapy in patients with atrial fibrillation on the regional level. <i>Meditinskiy Sovet</i> , <b>2020</b> , 19-25	0.4	